Research programme: bovine-derived polyclonal antibodies - Immuron

Drug Profile

Research programme: bovine-derived polyclonal antibodies - Immuron

Alternative Names: Bovine colostrum powder therapeutics - Immuron; Hyper immune anti UPEC product - Immuron; IMM 160; IMM 252 (HIV microbicide); IMM 529; Shigella vaccine - Immuron/Walter Reed Army Institute of Research

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Immuron
  • Developer Immuron; Monash University
  • Class Polyclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Clostridium infections; Urinary tract infections
  • No development reported HIV infections; Liver cancer

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Liver-cancer in Australia (PO)
  • 16 Jul 2016 No recent reports of development identified for research development in HIV-infections in Australia (PO)
  • 12 Jan 2016 Data from a preclinical study in Clostridium infections released by Immuron
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top